NPM-ALK modulates the p53 tumour suppressor pathway in a JNK and PI 3-Kinase dependent manner: MDM-2 is a potential therapeutic target for the treatment of ALK-expressing malignancies
Cui, Y, Kerby, A, McDuff, F.K.E, Turner, S.D
Published in European journal of cancer supplements (2008)
Published in European journal of cancer supplements (2008)
Get full text
Journal Article